leucine rich repeat containing 37 member A11, pseudogeneGenealiases: []
Q-omics provides the consensus-scored LRRC37A11P profile across patient tissues and cancer cell-line models. LRRC37A11P expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LRRC37A11P is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, LRRC37A11P RNA expression shows 15,457 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where LRRC37A11P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC37A11P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC37A11P survival associations across molecular data types. LRRC37A11P RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC37A11P RNA expression–survival associations across cancer types. High LRRC37A11P expression shows unfavorable associations in LIHC, STAD and BLCA, but favorable associations in KIRC, COAD and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LRRC37A11P RNA expression.
This table summarizes LRRC37A11P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC37A11P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC37A11P shows lower tumor expression in KIRC, KIRP, KICH, THCA, LUSC and HNSC. The KIRC box plot shows higher LRRC37A11P RNA expression in normal versus tumor tissue (log2 FC = −0.293, t-test p < 0.001).
This table shows molecular features associated with LRRC37A11P in patient tissues and cancer cell lines. In patient samples, LRRC37A11P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC37A11P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT.
